Literature DB >> 21367855

Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Xue-Yuan Dong1, Peng Guo, Xiaodong Sun, Qunna Li, Jin-Tang Dong.   

Abstract

The proper level of estrogen-estrogen receptor (ER) signaling is important for the maintenance of epithelial homeostasis in the breast. In a previous study we demonstrated that ATBF1, which has been suggested as a tumor suppressor in breast cancer, inhibited estrogen-mediated cell proliferation by selectively competing with AIB1 for binding to the ER. However, the expression of ATBF1 mRNA was shown to positively correlate with ER in breast cancer specimens. We, therefore, examined whether estrogen regulates ATBF1. We demonstrated that estrogen up-regulated the transcription of ATBF1, which was mediated by the direct binding of the ER onto the ATBF1 promoter, and that a half-estrogen-responsive element in the ATBF1 promoter was essential for ER direct binding. Furthermore, we found that estrogen at lower levels increased, but at higher levels decreased the expression of ATBF1 protein, which involved the degradation of ATBF1 protein by the estrogen-responsive proteasome system. ATBF1 protein levels fluctuate with estrogen levels. Although lower levels of estrogen increased ATBF1 protein expression, ATBF1 still inhibited cell proliferation caused by lower levels of estrogen. These findings not only reveal an autoregulatory feedback loop between ATBF1 and estrogen-ER signaling but also suggest that ATBF1 plays a role in both the maintenance of breast epithelial homeostasis and breast tumorigenesis caused by elevated estrogen levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367855      PMCID: PMC3077589          DOI: 10.1074/jbc.M110.187849

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Genetic alterations of the ATBF1 gene in gastric cancer.

Authors:  Yong Gu Cho; Jae Hwi Song; Chang Jae Kim; Youn Soo Lee; Su Young Kim; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.

Authors:  Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong
Journal:  Hum Mol Genet       Date:  2008-01-17       Impact factor: 6.150

3.  Identification of transcriptional regulatory elements in the human somatostatin receptor sst2 promoter and regions including estrogen response element half-site for estrogen activation.

Authors:  Nobuko Kimura; Nobuko Takamatsu; Yoshio Yaoita; R Yoshiyuki Osamura; Narimichi Kimura
Journal:  J Mol Endocrinol       Date:  2008-02       Impact factor: 5.098

Review 4.  Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Authors:  Grazia Arpino; Lisa Wiechmann; C Kent Osborne; Rachel Schiff
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

5.  The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

Authors:  Mark P Fereshteh; Maddalena T Tilli; Sung Eun Kim; Jianming Xu; Bert W O'Malley; Anton Wellstein; Priscilla A Furth; Anna T Riegel
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

6.  CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1.

Authors:  Seth Frietze; Mathieu Lupien; Pamela A Silver; Myles Brown
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  Down-regulation of ATBF1 is a major inactivating mechanism in hepatocellular carcinoma.

Authors:  C J Kim; J H Song; Y G Cho; Z Cao; Y S Lee; S W Nam; J Y Lee; W S Park
Journal:  Histopathology       Date:  2008-02-23       Impact factor: 5.087

Review 8.  Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity.

Authors:  E Cottone; F Orso; N Biglia; P Sismondi; M De Bortoli
Journal:  Int J Biol Markers       Date:  2001 Jul-Sep       Impact factor: 3.248

9.  ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.

Authors:  Anne-Marie Cleton-Jansen; Ronald van Eijk; Marcel Lombaerts; Marjanka K Schmidt; Laura J Van't Veer; Katja Philippo; Rhyenne M E Zimmerman; Johannes L Peterse; Vincent T B H M Smit; Tom van Wezel; Cees J Cornelisse
Journal:  BMC Cancer       Date:  2008-04-16       Impact factor: 4.430

10.  Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer.

Authors:  Kazuharu Kai; Zhenhuan Zhang; Hiroko Yamashita; Yutaka Yamamoto; Yutaka Miura; Hirotaka Iwase
Journal:  BMC Cancer       Date:  2008-09-16       Impact factor: 4.430

View more
  15 in total

1.  The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells.

Authors:  Changying Fu; Na An; Jinming Liu; Jun A; Baotong Zhang; Mingcheng Liu; Zhiqian Zhang; Liya Fu; Xinxin Tian; Dan Wang; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2020-04-10       Impact factor: 5.157

2.  Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP.

Authors:  Xue-Yuan Dong; Xiaoying Fu; Songqing Fan; Peng Guo; Dan Su; Jin-Tang Dong
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

3.  SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.

Authors:  Rui Wu; Jiali Fang; Mingcheng Liu; Jun A; Jinming Liu; Wenxuan Chen; Juan Li; Gui Ma; Zhiqian Zhang; Baotong Zhang; Liya Fu; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2020-04-05       Impact factor: 5.157

4.  A complex insertion/deletion polymorphism in the compositionally biased region of the ZFHX3 gene in patients with coronary heart disease in a Chinese population.

Authors:  Shunchang Sun; Wenwu Zhang; Xi Chen; Yunsheng Peng; Qunrong Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15

5.  Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.

Authors:  Dan Zhao; Gui Ma; Xiaolin Zhang; Yuan He; Mei Li; Xueying Han; Liya Fu; Xue-Yuan Dong; Tamas Nagy; Qiang Zhao; Li Fu; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2016-04-20       Impact factor: 5.157

6.  Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; Joseph P McElroy; Kevin R Coombes; Ralf Bundschuh; David E Cohn; David G Mutch; Paul J Goodfellow
Journal:  J Natl Cancer Inst       Date:  2015-09-01       Impact factor: 13.506

7.  ATBF1 Participates in Dual Functions of TGF-β via Regulation of Gene Expression and Protein Translocalization.

Authors:  Mei Li; Anqi Zhang; Yanan Zheng; Jiajing Li; Jiyuan Zhao
Journal:  Biomolecules       Date:  2020-05-24

8.  Atbf1 regulates pubertal mammary gland development likely by inhibiting the pro-proliferative function of estrogen-ER signaling.

Authors:  Mei Li; Xiaoying Fu; Gui Ma; Xiaodong Sun; Xueyuan Dong; Tamas Nagy; Changsheng Xing; Jie Li; Jin-Tang Dong
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.

Authors:  Xiaodong Sun; Xiaoying Fu; Jie Li; Changsheng Xing; Henry F Frierson; Hao Wu; Xiaokun Ding; Tongzhong Ju; Richard D Cummings; Jin-Tang Dong
Journal:  Neoplasia       Date:  2014-06-14       Impact factor: 5.715

10.  Long noncoding RNA DANCR promotes invasion of prostate cancer through epigenetically silencing expression of TIMP2/3.

Authors:  Jing Jia; Feng Li; Xiao-Shuang Tang; Shan Xu; Yang Gao; Qi Shi; Wenhuan Guo; Xinyang Wang; Dalin He; Peng Guo
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.